CTOs on the Move

Alzheon

www.alzheon.com

 
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.alzheon.com
  • 111 Speen Street Suite 306
    Framingham, MA USA 01701
  • Phone: 508.861.7709

Executives

Name Title Contact Details

Funding

Alzheon raised $47M on 08/20/2020

Similar Companies

Biothera, the Immune Health Company

Biothera, the Immune Health Company is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Reaction Biology

Reaction Biology provides scientists worldwide with a trusted research partner supporting all phases of preclinical drug discovery from target validation through hit identification, hit to lead and lead optimization. Our portfolio covers most of your needs in drug discovery – over 1,000 biochemical targets, hundreds of cell-based assays, an extensive array of in vivo oncology models, along with custom assay development and protein production. Our team of Ph.D. scientists will provide you with collaborative support, quality data, and excellent communication, for a superior research result.

VitroLabs

We cultivate authentic materials without compromise,by harnessing science and nature responsibly by partnering the most innovative minds in science and technology with the finest craftspeople to accelerate the use of cellular agriculture for good.

Patara Pharma

Patara Pharma is a biopharmaceutical company developing a new therapy for the treatment of allergic and immunologic diseases and conditions that affect orphan patient populations. We completed a Phase 1 clinical trial with favorable results and have initiated Phase 2 clinical trials for several undisclosed indications that will read-out by the end of 2015.

Tectonic Therapeutic

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.